PROfertil® female Study Results
Outcome parameters:
1) embryo quality on day 3 after oocyte retrieval (good quality vs. poor quality) and clinical pregnancy rate.
2) clinical pregnancy rate.
Results:
In an intention-to-treat analyses, a higher rate of women with at least one good quality embryo (with at least 6 cells and a fragmentation rate <20%) were found for the study (29/50, 58.0%) compared to the control group (18/50, 36.0%; p = 0.045 in chi-square test; relative risk 1.611, 95% CI 1.009–2.597).
Conclusion:
Profertil® female supplementation, given for a minimum of 28 days prior to ovarian hyperstimulation, is beneficial in terms of fertilization rate and embryo quality.
Practical Benefits:
After minimum intake duration, prior to ovarian stimulation, and with no side effects, Profertil® female may:
- significantly increase fertilization rate in comparison to folic acid alone,
- significantly increase embryo quality in comparison to folic acid alone, and
- improve clinical pregnancy rate in comparison to folic acid alone.